2024-02-22 13:12:05 ET
Kymera Therapeutics, Inc. (KYMR)
Q4 2023 Earnings Conference Call
February 22, 2024 8:30 AM ET
Company Participants
Justine Koenigsberg – Vice President-Investor Relations
Nello Mainolfi – President and Chief Executive Officer
Jared Gollob – Chief Medical Officer
Bruce Jacobs – Chief Financial Officer
Conference Call Participants
Vikram Purohit – Morgan Stanley
Adam Vogel – Wells Fargo
Marc Frahm – TD Cowen
Brad Canino – Stifel
Kalpit Patel – B. Riley Securities
Presentation
Operator
Good morning, and welcome to the Kymera Therapeutics Fourth Quarter 2023 Results Call. All participant lines will be in the listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note, this event is being recorded.
I’ll now turn the conference over to Justine Koenigsberg. Thank you. Please go ahead.
Justine Koenigsberg
Good morning, and welcome to Kymera’s investor update. Joining me this morning are Nello Mainolfi, President and CEO; Jared Gollob, our Chief Medical Officer and Bruce Jacobs, our Chief Financial Officer.
Following our prepared remarks, we will open the call to questions. We ask that you limit your questions to one and a relevant follow-up to allow enough time to address everyone’s questions. Before we begin, today’s discussion will include forward-looking statements about our future expectations, plans, and prospects. These statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected.
A description of these risks can be found in our most recent 10-Q filed with the SEC. Any forward-looking statements speak only as of today’s date, and we assume no obligation to update any forward-looking statements made on today’s call.
With that, I will now turn the call over to Nello.
Nello Mainolfi
Thank you, Justine. As always, we appreciate everyone joining us for our quarterly call today. This is a particularly exciting call for us, in that we’re reporting from our new corporate headquarters in Watertown, Massachusetts, just down the road from our previous office. Our new building provides added space for our growing team, enabling us to maintain a strong on-site presence as we enhance and scale critical capabilities for our R&D organization, especially in areas like CMC, as well as other development functions....
Read the full article on Seeking Alpha
For further details see:
Kymera Therapeutics, Inc. (KYMR) Q4 2023 Earnings Call Transcript